Nektar Therapeutics Research and Development Expense
Nektar Therapeutics (NKTR) reported Research and Development Expense of $39.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Nektar Therapeutics research and development expense for the quarter ending 2026-06-30 was $39.13M, a 30.93% increase year-over-year.
- Nektar Therapeutics research and development expense for the quarter ending 2026-03-31 was $35.68M, a 17.06% increase year-over-year.
- Nektar Therapeutics research and development expense for the quarter ending 2025-12-31 was $29.71M, a 3.36% increase year-over-year.
- Nektar Therapeutics research and development expense for the quarter ending 2025-09-30 was $27.25M, a 22.21% decline year-over-year.
- Nektar Therapeutics research and development expense for fiscal 2025 was $117.33M, a 2.96% decline from fiscal 2024.
- Nektar Therapeutics research and development expense for fiscal 2024 was $120.91M, a 5.91% increase from fiscal 2023.
- Nektar Therapeutics research and development expense for fiscal 2023 was $114.16M, a 47.71% decline from fiscal 2022.
- Nektar Therapeutics research and development expense for fiscal 2022 was $218.32M, a 45.46% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.13M 10-Q · filed 2026-08-14 | $74.81M 10-Q · filed 2026-08-14 | $104.52M derived: sum of 3 quarters · filed 2026-08-14 | $131.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $35.68M 10-Q · filed 2026-05-08 | $65.39M derived: sum of 2 quarters · filed 2026-05-08 | $92.64M derived: sum of 3 quarters · filed 2026-05-08 | $122.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $29.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $56.96M derived: sum of 2 quarters · filed 2026-03-13 | $86.85M derived: sum of 3 quarters · filed 2026-08-14 | $117.33M 10-K · filed 2026-03-13 |
| 2025-09-30 | $27.25M 10-Q · filed 2025-11-07 | $57.14M derived: sum of 2 quarters · filed 2026-08-14 | $87.62M 10-Q · filed 2025-11-07 | $116.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $29.89M 10-Q · filed 2026-08-14 | $60.37M 10-Q · filed 2026-08-14 | $89.11M derived: sum of 3 quarters · filed 2026-08-14 | $124.14M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $30.48M 10-Q · filed 2026-05-08 | $59.23M derived: sum of 2 quarters · filed 2026-05-08 | $94.26M derived: sum of 3 quarters · filed 2026-05-08 | $123.98M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $28.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $63.78M derived: sum of 2 quarters · filed 2026-03-13 | $93.50M derived: sum of 3 quarters · filed 2026-03-13 | $120.91M 10-K · filed 2026-03-13 |
| 2024-09-30 | $35.03M 10-Q · filed 2025-11-07 | $64.75M derived: sum of 2 quarters · filed 2025-11-07 | $92.16M 10-Q · filed 2025-11-07 | $122.11M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $29.72M 10-Q · filed 2025-08-08 | $57.13M 10-Q · filed 2025-08-08 | $87.07M derived: sum of 3 quarters · filed 2025-08-08 | $111.14M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $27.41M 10-Q · filed 2025-05-09 | $57.35M derived: sum of 2 quarters · filed 2025-05-09 | $81.42M derived: sum of 3 quarters · filed 2025-05-09 | $111.10M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $29.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $54.01M derived: sum of 2 quarters · filed 2025-03-14 | $83.69M derived: sum of 3 quarters · filed 2025-03-14 | $114.16M 10-K · filed 2025-03-14 |
| 2023-09-30 | $24.07M 10-Q · filed 2024-11-08 | $53.75M derived: sum of 2 quarters · filed 2024-11-08 | $84.22M 10-Q · filed 2024-11-08 | $118.96M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $29.68M 10-Q · filed 2024-08-09 | $60.15M 10-Q · filed 2024-08-09 | $94.89M derived: sum of 3 quarters · filed 2024-08-09 | $128.48M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $30.47M 10-Q · filed 2024-05-10 | $65.21M derived: sum of 2 quarters · filed 2024-05-10 | $98.80M derived: sum of 3 quarters · filed 2024-05-10 | $141.54M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $68.33M derived: sum of 2 quarters · filed 2024-03-05 | $111.07M derived: sum of 3 quarters · filed 2024-03-05 | $218.32M 10-K · filed 2024-03-05 |
| 2022-09-30 | $33.59M 10-Q · filed 2023-11-08 | $76.33M derived: sum of 2 quarters · filed 2023-11-08 | $183.58M 10-Q · filed 2023-11-08 | $283.20M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $42.74M 10-Q · filed 2023-08-09 | $149.99M 10-Q · filed 2023-08-09 | $249.61M derived: sum of 3 quarters · filed 2023-08-09 | $353.35M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $107.25M 10-Q · filed 2023-05-10 | $206.87M derived: sum of 2 quarters · filed 2023-05-10 | $310.61M derived: sum of 3 quarters · filed 2023-05-10 | $411.92M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $99.61M 10-K · filed 2022-03-01 | $203.35M derived: sum of 2 quarters · filed 2022-11-04 | $304.67M derived: sum of 3 quarters · filed 2022-11-04 | $400.27M 10-K · filed 2024-03-05 |
| 2021-09-30 | $103.74M 10-Q · filed 2022-11-04 | $205.05M derived: sum of 2 quarters · filed 2022-11-04 | $300.65M 10-Q · filed 2022-11-04 | $403.38M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $101.31M 10-Q · filed 2022-08-05 | $196.92M 10-Q · filed 2022-08-05 | $299.64M derived: sum of 3 quarters · filed 2022-08-05 | $400.17M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $95.60M 10-Q · filed 2022-05-06 | $198.33M derived: sum of 2 quarters · filed 2022-05-06 | $298.86M derived: sum of 3 quarters · filed 2022-05-06 | $395.30M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $102.72M 10-K · filed 2022-03-01 | $203.25M derived: sum of 2 quarters · filed 2022-03-01 | $299.69M derived: sum of 3 quarters · filed 2022-03-01 | $408.68M 10-K · filed 2023-02-28 |
| 2020-09-30 | $100.53M 10-K · filed 2022-03-01 | $196.97M derived: sum of 2 quarters · filed 2022-03-01 | $305.95M 10-Q · filed 2021-11-05 | $416.32M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $96.44M 10-K · filed 2022-03-01 | $205.42M 10-Q · filed 2021-08-06 | $315.79M derived: sum of 3 quarters · filed 2022-03-01 | $414.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $108.99M 10-K · filed 2022-03-01 | $219.36M derived: sum of 2 quarters · filed 2022-03-01 | $318.40M derived: sum of 3 quarters · filed 2022-03-01 | $425.09M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $110.37M 10-K · filed 2021-02-26 | $209.42M derived: sum of 2 quarters · filed 2021-02-26 | $316.10M derived: sum of 3 quarters · filed 2021-02-26 | $434.57M 10-K · filed 2022-03-01 |
| 2019-09-30 | $99.05M 10-K · filed 2021-02-26 | $205.73M derived: sum of 2 quarters · filed 2021-02-26 | $324.20M 10-Q · filed 2020-11-06 | $433.08M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $106.69M 10-K · filed 2021-02-26 | $225.15M 10-Q · filed 2020-08-07 | $334.03M derived: sum of 3 quarters · filed 2021-02-26 | $436.93M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $118.46M 10-K · filed 2021-02-26 | $227.35M derived: sum of 2 quarters · filed 2021-02-26 | $330.24M derived: sum of 3 quarters · filed 2021-02-26 | $418.57M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $108.88M 10-K · filed 2020-02-28 | $211.78M derived: sum of 2 quarters · filed 2020-02-28 | $300.11M derived: sum of 3 quarters · filed 2020-02-28 | $399.54M 10-K · filed 2021-02-26 |
| 2018-09-30 | $102.89M 10-K · filed 2020-02-28 | $191.23M derived: sum of 2 quarters · filed 2020-02-28 | $290.65M 10-Q · filed 2019-11-07 | $372.08M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $88.33M 10-K · filed 2020-02-28 | $187.76M 10-Q · filed 2019-08-09 | $269.19M derived: sum of 3 quarters · filed 2020-02-28 | $334.90M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $99.42M 10-K · filed 2020-02-28 | $180.85M derived: sum of 2 quarters · filed 2020-02-28 | $246.57M derived: sum of 3 quarters · filed 2020-02-28 | $306.83M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $81.43M 10-K · filed 2019-03-01 | $147.14M derived: sum of 2 quarters · filed 2019-03-01 | $207.40M derived: sum of 3 quarters · filed 2019-03-01 | $268.46M 10-K · filed 2020-02-28 |
| 2017-09-30 | $65.71M 10-K · filed 2019-03-01 | $125.97M derived: sum of 2 quarters · filed 2019-03-01 | $187.03M 10-Q · filed 2018-11-08 | $237.26M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $60.26M 10-K · filed 2019-03-01 | $121.32M 10-Q · filed 2018-08-09 | $171.55M derived: sum of 3 quarters · filed 2019-03-01 | $223.50M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $61.06M 10-K · filed 2019-03-01 | $111.29M derived: sum of 2 quarters · filed 2019-03-01 | $163.24M derived: sum of 3 quarters · filed 2019-03-01 | $215.59M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $50.23M 10-K · filed 2018-03-01 | $102.18M derived: sum of 2 quarters · filed 2018-03-01 | $154.53M derived: sum of 3 quarters · filed 2018-03-01 | $203.80M 10-K · filed 2019-03-01 |
| 2016-09-30 | $51.95M 10-K · filed 2018-03-01 | $104.30M derived: sum of 2 quarters · filed 2018-03-01 | $153.57M 10-Q · filed 2017-11-08 | $200.70M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $52.35M 10-K · filed 2018-03-01 | $101.62M 10-Q · filed 2017-08-09 | $148.75M derived: sum of 3 quarters · filed 2018-03-01 | $191.98M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $49.27M 10-K · filed 2018-03-01 | $96.40M derived: sum of 2 quarters · filed 2018-03-01 | $139.63M derived: sum of 3 quarters · filed 2018-03-01 | $185.04M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $47.13M 10-K · filed 2017-03-01 | $90.36M derived: sum of 2 quarters · filed 2017-03-01 | $135.78M derived: sum of 3 quarters · filed 2017-03-01 | $182.79M 10-K · filed 2018-03-01 |
| 2015-09-30 | $43.23M 10-K · filed 2017-03-01 | $88.64M derived: sum of 2 quarters · filed 2017-03-01 | $135.65M 10-Q · filed 2016-11-04 | $174.15M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $45.41M 10-K · filed 2017-03-01 | $92.42M 10-Q · filed 2016-08-04 | $130.92M derived: sum of 3 quarters · filed 2017-03-01 | $165.12M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $47.01M 10-K · filed 2017-03-01 | $85.50M derived: sum of 2 quarters · filed 2017-03-01 | $119.70M derived: sum of 3 quarters · filed 2017-03-01 | $156.41M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $38.49M 10-K · filed 2016-02-29 | $72.69M derived: sum of 2 quarters · filed 2016-02-29 | $109.40M derived: sum of 3 quarters · filed 2016-02-29 | $147.73M 10-K · filed 2017-03-01 |
| 2014-09-30 | $34.20M 10-K · filed 2016-02-29 | $70.90M derived: sum of 2 quarters · filed 2016-02-29 | $109.24M 10-Q · filed 2015-11-06 | $157.49M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $36.70M 10-K · filed 2016-02-29 | $75.04M 10-Q · filed 2015-08-06 | $123.29M derived: sum of 3 quarters · filed 2016-02-29 | $167.20M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $38.34M 10-K · filed 2016-02-29 | $86.59M derived: sum of 2 quarters · filed 2016-02-29 | $130.50M derived: sum of 3 quarters · filed 2016-02-29 | $182.73M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $48.25M 10-K · filed 2015-02-26 | $92.16M derived: sum of 2 quarters · filed 2015-02-26 | $144.39M derived: sum of 3 quarters · filed 2015-02-26 | $190.01M 10-K · filed 2016-02-29 |
| 2013-09-30 | $43.91M 10-K · filed 2015-02-26 | $96.14M derived: sum of 2 quarters · filed 2015-02-26 | $141.76M 10-Q · filed 2014-11-07 | $188.13M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $52.23M 10-K · filed 2015-02-26 | $97.85M 10-Q · filed 2014-08-01 | $144.22M derived: sum of 3 quarters · filed 2015-02-26 | $178.24M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $45.62M 10-K · filed 2015-02-26 | $91.99M derived: sum of 2 quarters · filed 2015-02-26 | $126.01M derived: sum of 3 quarters · filed 2015-02-26 | $159.21M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $46.37M 10-K · filed 2014-02-27 | $80.39M derived: sum of 2 quarters · filed 2014-02-27 | $113.59M derived: sum of 3 quarters · filed 2014-02-27 | $148.68M 10-K · filed 2015-02-26 |
| 2012-09-30 | $34.02M 10-K · filed 2014-02-27 | $67.22M derived: sum of 2 quarters · filed 2014-02-27 | $102.30M 10-Q · filed 2013-11-07 | $135.60M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $33.20M 10-K · filed 2014-02-27 | $68.29M 10-Q · filed 2013-08-09 | $101.59M derived: sum of 3 quarters · filed 2014-02-27 | $132.61M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $35.09M 10-K · filed 2014-02-27 | $68.39M derived: sum of 2 quarters · filed 2014-02-27 | $99.41M derived: sum of 3 quarters · filed 2014-02-27 | $131.68M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $33.30M 10-K · filed 2013-03-01 | $64.32M derived: sum of 2 quarters · filed 2013-03-01 | $96.59M derived: sum of 3 quarters · filed 2013-03-01 | $126.77M 10-K · filed 2014-02-27 |
| 2011-09-30 | $31.02M 10-K · filed 2013-03-01 | $63.29M derived: sum of 2 quarters · filed 2013-03-01 | $93.46M 10-Q · filed 2012-11-09 | $124.92M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $32.27M 10-K · filed 2013-03-01 | $62.45M 10-Q · filed 2012-08-09 | $93.90M derived: sum of 3 quarters · filed 2013-03-01 | $121.63M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $30.18M 10-K · filed 2013-03-01 | $61.63M derived: sum of 2 quarters · filed 2013-03-01 | $89.36M derived: sum of 3 quarters · filed 2013-03-01 | $114.95M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $31.45M 10-K · filed 2012-02-29 | $59.18M derived: sum of 2 quarters · filed 2012-02-29 | $84.78M derived: sum of 3 quarters · filed 2012-02-29 | $108.06M 10-K · filed 2013-03-01 |
| 2010-09-30 | $27.72M 10-K · filed 2012-02-29 | $53.32M derived: sum of 2 quarters · filed 2012-02-29 | $76.61M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $25.60M 10-K · filed 2012-02-29 | $48.89M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $23.29M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | $95.11M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |